Table 2.
Strains used in this study or tested in the colony immunoblot.
| Blot Position | Species, strain | Capsule type | Description or source | Ref. or source |
|---|---|---|---|---|
| Staphylococcus spp. | ||||
| A3 | S. epidermidis RP62A | NA | Biofilm producing, methicillin-resistant strain | 65 |
| A4 | S. haemolyticus JCSC 1435 | NA | Sequenced strain from a Japanese patient in Tokyo | 66 |
| A5 | S. saprophyticus 15305 | NA | ATCC; genome sequenced uropathogenic isolate | 67 |
| A6 | S. lugdunensis 45–6447 | NA | Bacteremia isolate from 2014 | BWHa |
| Staphylococcus aureus | ||||
| B1 | Newman | 5 | Human isolate from 1952 | 68 |
| B2 | Mu50 | 5 | Vancomycin-intermediate MRSA isolate; Japan | 69 |
| B3 | COL | 5 | MRSA strain with SCCmecII | 65 |
| B4 | 502A | 5 | Strain adept at colonization | 70 |
| B5 | NRS 382 | 5 | USA100 MRSA | NARSAb |
| B6 | NRS 383 | 5 | USA200 MRSA | NARSA |
| B7 | NRS 386 | 5 | USA700 MRSA | NARSA |
| C1 | Lowenstein | 5 | Nabi serotype 5 reference strain | 71 |
| C2 | Reynolds (CP5) | 5 | Prototype CP5+ strain | 17 |
| C3 | Reynolds Δcap5H | 5 | Produces WT levels of O-deacetylated CP5 | 51 |
| C4 | Crimson 5313 | 5 | Bacteremia isolate from 2012 | BWH |
| C5 | Crimson 18207 | 5 | Bacteremia MRSA isolate from 2013 | BWH |
| C6 | 29213 | 5 | Antibiotic susceptibility testing reference strain | ATCC |
| C7 | ST22 #15 | 5 | CA-MRSAc from 2010; Regensburg, Germany | F. Hanses |
| D1 | MN8 | 8 | Menstrual toxic shock isolate | 72 |
| D2 | ST80–16 | 8 | CA-MRSA strain from 2010; Regensburg, FRG | 73 |
| D3 | Wright | 8 | Nabi serotype 8 reference strain | 71 |
| D4 | PS80 | 8 | ATCC 27700 | 58 |
| D5 | Becker | 8 | Prototype CP8+ strain | 74 |
| D6 | V8 | 8 | Source of staphylococcal V8 protease | 75 |
| D7 | HS-522 | 8 | ST239 MRSA | 76 |
| E1 | NRS 387 | 8 | USA800 MRSA | NARSA |
| E2 | NRS 483 | 8 | USA1000 MRSA | NARSA |
| E3 | NRS 484 | 8 | USA1100 MRSA | NARSA |
| E4 | GFRY | 8 | Bacteremia isolate from 1997 | BWH |
| E5 | VP | 8 | Bacteremia isolate from 1995 | 41 |
| E6 | JP122 | 8 | Bacteremia isolate from 1990 | BWH |
| E7 | JP136 | 8 | Bacteremia isolate from 1990 | BWH |
| F1 | 25923 | 8 | Seattle 1945; antibiotic reference strain | ATCC |
| F2 | Reynolds (CP8) | 8 | Reynolds genetically modified to produce CP8 | 17 |
| F3 | UAMS-1 | 8 | Genome sequenced musculoskeletal isolate | 77 |
| F4 | 2672 | 8 | USA400; necrotizing pneumonia and sepsis isolate | 32 |
| F5 | RF122 | 8 | Genome sequenced bovine isolate | 78 |
| F6 | Sanger 252 | 8 | Epidemic MRSA clone | 31 |
| F7 | MW2 | 8 | Community acquired MRSA; USA400 | 79 |
| G1 | Sanger 476 | CP- | Community acquired MSSA; USA400 | 31 |
| G2 | 8325–4 | CP- | NCTC; cured of three prophages | 80 |
| G3 | LAC | CP- | Los Angeles clone; USA300 MRSA | 81 |
| G4 | NRS 482 | CP- | USA300 MRSA | NARSA |
| G5 | NRS 691 | CP- | USA500 MRSA | NARSA |
| G6 | Cowan I | CP- | Isolate with high protein A expression | 82 |
| G7 | Reynolds (CP-) | CP- | Reynolds acapsular mutant | 17 |
Note.
a
BWH, Brigham and Women's Hospital, Boston, MA.
b
NARSA, Network on Antimicrobial Resistance in Staphylococcus aureus.
c
CA-MRSA, community-acquired methicillin resistant Staphylococcus aureus.